Nuvation Bio’s IBTROZI Label Now Shows More Than Four Years of Response
FDA approved an IBTROZI label update showing 49.7 months median response in TKI-naïve ROS1+ lung cancer. Safety language was unchanged.
/ 8 items
#NUVB↓
What Makes Nuvation Bio a “Low-Risk, High-Reward” Stock According to Cantor
Cantor Fitzgerald starts coverage of Nuvation Bio at Overweight, citing a low-risk oncology story with upside from Ibtrozi and safusidenib.
Nuvation Bio: JPMorgan Sees Strong Ibtrozi Launch and Pipeline Upside
JPMorgan initiates Nuvation Bio at Overweight with $13 target, citing durable first-line adoption of Ibtrozi in ROS1+ lung cancer.
RBC Bullish on Nuvation Bio as Safusidenib Delivers Durable Responses in Glioma with New Phase 3 and Phase 2 Studies
Nuvation Bio reports strong long-term Phase 2 data for safusidenib (52% ORR, 79% PFS) and announces new Phase 3 and Phase 2 studies in IDH1-mutant glioma.
Biotech Earnings Preview: Mixed Results Send Stocks on Divergent Paths
Nuvation Bio and Sarepta shares tumble on disappointing preliminary results while Adaptive Biotechnologies surges on strong revenue beat.
Clear Street Maintains Buy on Nuvation Bio Despite Pipeline Adjustment
Clear Street keeps $12 price target on NUVB after NUV-1511 discontinuation, citing blockbuster potential for IBTROZI and safusidenib programs.